Ahmed Elsehemy

Dr. Ahmed Elsehemy


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
IMIssa Mohamad
Issa Mohamad
IKIrene Karam
Irene Karam
AEAhmed Elsehemy
Ahmed Elsehemy
IAIbrahim Abu-Gheida
Ibrahim Abu-Gheida
Akram Al-IbraheemAkram Al-Ibraheem
Akram Al-Ibraheem
AHAli Hosni
Ali Hosni
Stereotactic body radiation therapy (SBRT) is a precise and conformal radiation therapy (RT) that aims to deliver a high dose of radiation to the tumor whilst sparing surrounding normal tissue, making it an attractive option for head and neck cancer (HNC) patients who are not suitable for the traditional long course of RT with comprehensive RT target volume. Definitive SBRT for HNC has been investigated in different settings, including early stage glottis cancer, and as an alternative to brachytherapy boost after external beam RT. It is also used as a primary treatment option for elderly or medically unfit patients. More recently, an SBRT combination with immunotherapy in the neoadjuvant setting for HNC showed promising results. Salvage or adjuvant SBRT for HNC can be used in appropriately selected cases. Future studies are warranted to determine the optimum dose and fractionation schedules in any of these indications.

30 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
IMIssa Mohamad
Issa Mohamad
IKIrene Karam
Irene Karam
AEAhmed Elsehemy
Ahmed Elsehemy
IGIbrahim Abu Gheida
Ibrahim Abu Gheida
Akram Al-IbraheemAkram Al-Ibraheem
Akram Al-Ibraheem
AHAli Hosni
Ali Hosni
Stereotactic body radiation therapy (SBRT) is a precise and conformal radiation therapy (RT) that aims to deliver a high dose of radiation to the tumor with sparing surrounding normal tissue, making it an attractive option for head and neck cancer (HNC) patients who are not suitable for traditional long course of RT with comprehensive RT target volume. Definitive SBRT for HNC has been investigated in different settings, including early stage glottis cancer, and as alternative to brachytherapy boost after external beam RT. It also used as a primary treatment option for elderly or medically unfit patients. More recently, SBRT combination with immunotherapy in the neoadjuvant setting for HNC showed promising results. Salvage or adjuvant SBRT for HNC can be used in appropriately selected cases. Future studies are warranted to determine the optimum dose and fractionation schedules in any of these indications.